Immunogenicity and antigenicity of Plasmodium vivax merozoite surface protein 10

Parasitology Research

Volumn 113, Issue 7, 2014, Pages 2559-2568

  Cheng, Yang ^a   Wang, Bo ^a   Sattabongkot, Jetsumon ^b   Lim, Chae Seung ^c   Tsuboi, Takafumi ^d   Han, Eun Taek ^a  

^a Kangwon National University   (South Korea)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Korea University College of Medicine   (South Korea)

^d EHIME UNIVERSITY   (Japan)

Author keywords

Antigenicity; Immunogenicity; Merozoite surface; MSP 10; Plasmodium vivax

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 10; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SENSITIVITY AND SPECIFICITY; TH1 CELL;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; FEMALE; HUMANS; IMMUNE SERA; IMMUNIZATION; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, VIVAX; MEROZOITES; MICE; MICE, INBRED BALB C; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS;

EID: 84903781590     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-014-3907-8     Document Type: Article

References (38)

1. Alaro JR, Lynch MM, Burns JM Jr (2010) Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection. Vaccine 28:6876-6884
2. Angulo I, Fresno M (2002) Cytokines in the pathogenesis of and protection against malaria. Clin Diagn Lab Immunol 9:1145-1152 (Pubitemid 35283273)
3. Anstey NM, Russell B, Yeo TW, Price RN (2009) The pathophysiology of vivax malaria. Trends Parasitol 25:220-227
4. Arumugam TU, Takeo S, Yamasaki T, Thonkukiatkul A, Miura K, Otsuki H, Zhou H, Long CA, Sattabongkot J, Thompson J, Wilson DW, Beeson JG, Healer J, Crabb BS, Cowman AF, Torii M, Tsuboi T (2011) Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen. Infect Immun 79:4523-4532
5. Aucan C, Traore Y, Tall F, Nacro B, Traore-Leroux T, Fumoux F, Rihet P (2000) High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria. Infect Immun 68:1252-1258 (Pubitemid 30108518)
6. Bang G, Prieur E, Roussilhon C, Druilhe P (2011) Pre-clinical assessment of novel multivalentMSP3 malaria vaccine constructs. PLoS One 6:e28165
7. + T cells required for immune control of blood-stage malaria infection. J Immunol 186:4862-4871
8. Black CG, Wang L, Wu T, Coppel RL (2003) Apical location of a novel EGF-like domain-containing protein of Plasmodium falciparum. Mol Biochem Parasitol 127:59-68 (Pubitemid 36263232)
9. Branch OH, Oloo AJ, Nahlen BL, Kaslow D, Lal AA (2000) Antimerozoite surface protein-1 19-kDa IgG in mother-infant pairs naturally exposed to Plasmodium falciparum: subclass analysis with age, exposure to asexual parasitemia, and protection against malaria. V. The Asembo Bay Cohort Project. J Infect Dis 181:1746-1752 (Pubitemid 30387769)
10. Chen JH, Jung JW, Wang Y, Ha KS, Lu F, Lim CS, Takeo S, Tsuboi T, Han ET (2010) Immunoproteomics profiling of blood stage Plasmodium vivax infection by high-throughput screening assays. J Proteome Res 9:6479-6489
11. Cheng Y, Lu F, Tsuboi T, Han ET (2013a) Characterization of a novel merozoite surface protein of Plasmodium vivax, Pv41. Acta Trop 126:222-228
12. Cheng Y, Wang Y, Ito D, Kong DH, Ha KS, Chen JH, Lu F, Li J, Wang B, Takashima E, Sattabongkot J, Tsuboi T, Han ET (2013b) The Plasmodium vivax merozoite surface protein 1 paralog is a novel erythrocyte-binding ligand of P. vivax. Infect Immun 81:1585-1595
13. Collins WE, Kaslow DC, Sullivan JS, Morris CL, Galland GG, Yang C, Saekhou AM, Xiao L, Lal AA (1999) Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19)) of Plasmodium vivax in Saimiri boliviensis monkeys. Am J Trop Med Hyg 60:350-356 (Pubitemid 29162114)
14. Daher LJ, Demanga CG, Prieur E, Perignon JL, Bouharoun-Tayoun H, Druilhe P (2010) Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of immunogenicity studies in models. Infect Immun 78:477-485
15. Demanga CG, Daher LJ, Prieur E, Blanc C, Perignon JL, Bouharoun-Tayoun H, Druilhe P (2010) Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans. Infect Immun 78:486-494
16. Finney OC, Riley EM, Walther M (2010) Regulatory Tcells in malaria-friend or foe? Trends Immunol 31:63-70
17. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Muller I (2008) Plasmodium vivax andmixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 5:e127
18. Giraldo MA, Arevalo-Pinzon G, Rojas-Caraballo J, Mongui A, Rodriguez R, Patarroyo MA (2009) Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection. Vaccine 28:7-13
19. Herrera S, Corradin G, Arevalo-Herrera M (2007) An update on the search for a Plasmodium vivax vaccine. Trends Parasitol 23:122-128 (Pubitemid 46274505)
20. Kurtzhals JA, Adabayeri V, Goka BQ, Akanmori BD, Oliver-Commey JO, Nkrumah FK, Behr C, Hviid L (1998) Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria. Lancet 351:1768-1772 (Pubitemid 28269187)
21. Langhorne J, Ndungu FM, Sponaas AM, Marsh K (2008) Immunity to malaria: more questions than answers. Nat Immunol 9:725-732 (Pubitemid 351859155)
22. Lima-Junior JC, Tran TM, Meyer EV, Singh B, De-Simone SG, Santos F, Daniel-Ribeiro CT, Moreno A, Barnwell JW, Galinski MR, Oliveira-Ferreira J (2008) Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. Vaccine 26:6645-6654
23. Nogueira PA, Alves FP, Fernandez-Becerra C, Pein O, Santos NR, Pereira da Silva LH, Camargo EP, del Portillo HA (2006) A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. Infect Immun 74:2726-2733 (Pubitemid 43672981)
24. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, Filgueira MC, Tartar A, Druilhe P (1994) Merozoite surface protein-3: amalaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84:1594-1602 (Pubitemid 24273030)
25. Pacheco MA, Elango AP, Rahman AA, Fisher D, Collins WE, Barnwell JW, Escalante AA (2012) Evidence of purifying selection on merozoite surface protein 8 (MSP8) and 10 (MSP10) in Plasmodium spp. Infect Genet Evol 12:978-986
26. Perez-Leal O, Sierra AY, Barrero CA, Moncada C, Martinez P, Cortes J, Lopez Y, Salazar LM, Hoebeke J, Patarroyo MA (2005) Identifying and characterising the Plasmodium falciparum merozoite surface protein 10 Plasmodium vivax homologue. Biochem Biophys Res Commun 331:1178-1184 (Pubitemid 40692482)
27. Scholzen A, Minigo G, Plebanski M (2010) Heroes or villains? T regulatory cells in malaria infection. Trends Parasitol 26:16-25
28. Sirima SB, Cousens S, Druilhe P (2011) Protection against malaria by MSP3 candidate vaccine. N Engl J Med 365:1062-1064
29. Smith KA (1988) Interleukin-2: inception, impact, and implications. Science 240:1169-1176
30. Soares IS, Levitus G, Souza JM, Del Portillo HA, Rodrigues MM (1997) Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect Immun 65:1606-1614 (Pubitemid 27193576)
31. Taverne J, Tavernier J, Fiers W, Playfair JH (1987) Recombinant tumour necrosis factor inhibits malaria parasites in vivo but not in vitro. Clin Exp Immunol 67:1-4 (Pubitemid 17222153)
32. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN (2008) Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 5:e128
33. Tsuboi T, Takeo S, Iriko H, Jin L, Tsuchimochi M, Matsuda S, Han ET, Otsuki H, Kaneko O, Sattabongkot J, Udomsangpetch R, Sawasaki T, Torii M, Endo Y (2008) Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect Immun 76:1702-1708 (Pubitemid 351562015)
34. Tsuboi T, Takeo S, Sawasaki T, Torii M, Endo Y (2010) An efficient approach to the production of vaccines against the malaria parasite. Methods Mol Biol 607:73-83
35. Valderrama-Aguirre A, Quintero G, Gomez A, Castellanos A, Perez Y, Mendez F, Arevalo-Herrera M, Herrera S (2005) Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am J Trop Med Hyg 73:16-24 (Pubitemid 41688444)
36. Vargas-Serrato E, Barnwell JW, Ingravallo P, Perler FB, Galinski MR (2002) Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p101/ABRA of P. falciparum. Mol Biochem Parasitol 120:41-52 (Pubitemid 34159291)
37. White WI, Evans CB, Taylor DW (1991) Antimalarial antibodies of the immunoglobulin G2a isotype modulate parasitemias in mice infected with Plasmodium yoelii. Infect Immun 59:3547-3554
38. Zeyrek FY, Babaoglu A, Demirel S, Erdogan DD, Ak M, Korkmaz M, Coban C (2008) Analysis of naturally acquired antibody responses to the 19-kd C-terminal region of merozoite surface protein-1 of Plasmodium vivax from individuals in Sanliurfa, Turkey. Am J Trop Med Hyg 78:729-732 (Pubitemid 351845127)